Navigation Links
Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management
Date:6/17/2008

Move further expands PROMETRIKA's focus in key areas in contract research including clinical trial planning and execution, clinical monitoring, and

data management/electronic data capture.

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- PROMETRIKA, LLC, a contract research organization providing a full range of clinical research services for clients in pharmaceuticals, biologics and medical devices, today announced that Faith Haines Kolb has joined the company as senior director of clinical operations and data management. With more than 19 years of experience in clinical research, Ms. Kolb has set up and managed multiple large scale clinical research programs from planning through all phases of execution, data management, and reporting.

"Faith Haines Kolb is one of the most experienced clinical research professionals working in the field today. As we continue to expand our services in the clinical research areas that are critical for our clients at PROMETRIKA, her demonstrated strengths in project management, monitoring, electronic data capture, and working successfully with global research networks will be a tremendous asset for us moving forward," said Miganush Stepanians, PhD, president and CEO of PROMETRIKA.

Prior to joining PROMETRIKA, Ms. Kolb was chief technical officer at Averion International Corporation, an international clinical research organization. At Averion she was responsible for the company's operational performance in the United States. Prior to joining Averion, she was director of clinical IT at PAREXEL International Corporation.

"In my work I have seen the many challenges in pharmaceutical product development facing companies in the U.S. and around the world. With a strong focus on improving clinical research services for pharmaceutical, biotechnology and medical device companies, PROMETRIKA is setting a new standard in terms of efficiency and quality control for clinical trials. I am very pleased to be joining this dynamic team," Ms. Kolb added.

The clinical operations team at PROMETRIKA provides research planning and execution services to support product development in pharmaceuticals, biologics and medical devices for companies around the world. Team leaders are responsible for project planning and management, including monitoring enrollment, research schedules, third party vendor management, budgeting and performance metrics. They also coordinate services related to data management, biostatistics and medical writing for data collection and analysis, internal and external reporting, and regulatory filings.

According to a research study by CMSInfo, spending on clinical trials in the United States reached $24 billion in 2005, and it is projected to rise to $32.1 billion by 2011. The Congressional Budget Office in the United States estimates that by 2003 the average cost to develop a drug that represents a new molecular entity (NME) reached $802 million and the development timeline for NME drugs required an average of 7.5 years of clinical stage research.

"Increasingly, clients are looking to us for new approaches involving electronic data capture and other technologies that can maximize research efficiency without compromising quality and accuracy. With Faith's experience in these areas, PROMETRIKA is better prepared than ever before to be a comprehensive resource to help our clients plan and execute strategic and successful clinical research programs," Ms. Stepanians added.

About PROMETRIKA

Founded in 2003, PROMETRIKA, LLC, is a full service contract research organization with headquarters in Cambridge, MA. The company provides a full range of clinical research services to pharmaceutical, biotechnology and medical device companies. PROMETRIKA's team has managed hundreds of clinical trials from Phase 1 pharmacokinetic crossover trials to Phase 4 long-term multi-center studies. The company has extensive experience in all areas of clinical trial management, including strategic planning, data collection and analysis, and regulatory filings, including new drug applications in the U.S. and Europe. For additional information please visit http://www.prometrika.com.


'/>"/>
SOURCE PROMETRIKA, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
2. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. Hank Plain Joins Morgenthaler Ventures as Partner
5. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
6. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
7. Dan Broderick Joins Prolog Ventures as Partner
8. Ingenuity Systems Joins Biomarkers Consortium
9. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
10. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
11. Progeniq Joins Microsoft in Bio IT Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... 2016  Tempus, a technology company focused on ... Abramson Cancer Center have partnered to better determine ... immunotherapy treatment based on next generation genomic and ... a research collaboration, Tempus will provide sequencing and ... data to Penn. Utilizing next-generation sequencing, machine learning ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule ... of the latest FDA guidance on pharmaceutical cocrystals as drug substance . ... , The event follows the successful November 15th event that took place ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
Breaking Biology Technology:
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
Breaking Biology News(10 mins):